Vanda Pharmaceuticals (NASDAQ:VNDA) Lifted to “Buy” at StockNews.com

StockNews.com upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a hold rating to a buy rating in a research note published on Sunday.

Separately, TheStreet cut shares of Vanda Pharmaceuticals from a c- rating to a d rating in a research note on Thursday, February 8th.

Vanda Pharmaceuticals Stock Up 29.4 %

Shares of Vanda Pharmaceuticals stock opened at $5.24 on Friday. The firm has a market capitalization of $301.51 million, a P/E ratio of 106.22 and a beta of 0.76. The company has a 50 day moving average price of $4.17 and a 200 day moving average price of $4.05. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The firm had revenue of $45.27 million during the quarter, compared to analyst estimates of $37.00 million. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. As a group, research analysts anticipate that Vanda Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC grew its stake in Vanda Pharmaceuticals by 91.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,538 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 2,644 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 5,186 shares during the period. CWM LLC raised its holdings in Vanda Pharmaceuticals by 61.1% in the 3rd quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 2,732 shares during the period. PNC Financial Services Group Inc. raised its holdings in Vanda Pharmaceuticals by 46.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 2,904 shares during the period. Finally, Lazard Asset Management LLC raised its holdings in Vanda Pharmaceuticals by 263.0% in the 2nd quarter. Lazard Asset Management LLC now owns 9,718 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 7,041 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.